PD-1/PD-L1 inhibitors can target the inhibition of the PD-1/PD-L1 signaling pathway and induce the recombination of antigen peptide-histocompatibility complex (MHC) and T cell receptor (TCR), thus activating the anti-tumor immune response of T lymphocytes and inhibiting the growth of tumor cells [17, 18]. This evidence concerns the gene CD274 and neoplasm.